Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

67Cu SAR bombesin - Clarity Pharmaceuticals

Drug Profile

67Cu SAR bombesin - Clarity Pharmaceuticals

Alternative Names: 67Cu-SAR-BBN; 67Cu-SAR-bombesin - Clarity Pharmaceuticals; 67Cu-SAR-Bombesin; Copper-67-SAR-Bombesin; Cu67-SAR-Bombesin

Latest Information Update: 22 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clarity Pharmaceuticals
  • Class Antineoplastics; Neuropeptides; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 20 Jun 2023 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in USA (Parenteral) (NCT05633160)
  • 06 Dec 2022 Clarity Pharmaceuticals plans a phase I/IIa COMBAT trial for Prostate cancer (Metastatic, Hormone refractory) in USA (Parenteral) as of November 2022 (NCT05633160)
  • 21 Nov 2022 US FDA approves IND application for 67Cu SAR bombesin in Prostate cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top